Evidence map›Paper›PMID 31206841›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2020

Biomimetic Nanotechnology toward Personalized Vaccines.

Jiarong Zhou, Ashley V Kroll, Maya Holay, Ronnie H Fang, Liangfang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Materials today. Bio · 2026
    Article
  11. Review
  12. National science review · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiarong ZhouDepartment of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Ashley V KrollDepartment of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Maya HolayDepartment of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Ronnie H FangDepartment of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID https://orcid.org/0000-0003-0637-0654

Funding

Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
Defense Threat Reduction Agency HDTRA1-18-1-0014Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense HDTRA1-18-1-0014NCI NIH HHS T32 CA153915NIH HHS 5T32CA153915
6 · The paper itself

Abstract

While traditional approaches for disease management in the era of modern medicine have saved countless lives and enhanced patient well-being, it is clear that there is significant room to improve upon the current status quo. For infectious diseases, the steady rise of antibiotic resistance has resulted in super pathogens that do not respond to most approved drugs. In the field of cancer treatment, the idea of a cure-all silver bullet has long been abandoned. As a result of the challenges facing current treatment and prevention paradigms in the clinic, there is an increasing push for personalized therapeutics, where plans for medical care are established on a patient-by-patient basis. Along these lines, vaccines, both against bacteria and tumors, are a clinical modality that could benefit significantly from personalization. Effective vaccination strategies could help to address many challenging disease conditions, but current vaccines are limited by factors such as a lack of potency and antigenic breadth. Recently, researchers have turned toward the use of biomimetic nanotechnology as a means of addressing these hurdles. Recent progress in the development of biomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis on their potential for personalized medicine.

Indexed as

AnimalsBacterial InfectionsBacterial VaccinesBiomimetic MaterialsBiomimeticsCancer VaccinesDrug Delivery SystemsHumansNanomedicineNanoparticlesNanotechnologyNeoplasmsPrecision MedicineVaccinationBacterial VaccinesCancer Vaccinesanticancer vaccinationsbacteria vaccinationsbiomimetic nanoparticlesnanomedicinepersonalized medicine

Identifiers

PMID31206841
PMCPMC6918015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.